News

Qilu Pharmaceutical Ranks No. 8th among Top 100 Chinese Pharmaceutical Companies

ABOUT US

News

Qilu Pharmaceutical Ranks No. 8th among Top 100 Chinese Pharmaceutical Companies

Release time：

2019-08-30

On Aug. 25^th, 2019, the 36^th Pharmaceutical Industry information Annual Conference hosted by China National Pharmaceutical Industry Information Center was inaugurated in Lianyungang city, Jiangsu Province. The Top 100 Chinese Pharmaceutical Companies was released and Qilu Pharmaceutical ranks No. 8^th. The company was also awarded the best R&D pipeline company of 2019 at the event.

The first Avastin(Bevacizumab) Biosimilar approval in China granted by NMPA

Qilu Pharmaceutical recognized as Top 3 domestic R&D pharmaceutical company of 2019

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”